Haidar A. Abdulamir, Ameer A A Aldafaay, Ahmed Hamza Al-Shammari
Haidar A. Abdulamir1, Ameer A A Aldafaay2, Ahmed Hamza Al-Shammari3
1College of Pharmacy-Al-Maaql University, Basra-Iraq.
2Department of Pharmacy-Al-Turath University College, Baghdad- Iraq.
3Department of Pharmacy, Kut University College, Alkut, Wasit, Iraq, 52001.
Volume - 15,
Issue - 8,
Year - 2022
Background: Gaucher disease (GD) is an autosomal recessive hereditary disease. The etiology, pathophysiology, diagnosis, and prognosis of GD in children might all be affected by a variety of biomarkers. The majority of them are linked to abnormalities caused by this lysosomal storage disorder, which is caused by a deficiency of the glucocerebrosidase enzyme that affects numerous organs including the liver, spleen, and bones. Objectives: to investigate the relevance of liver function tests in the assessment of treatment response in children with Gaucher's disease who are undergoing enzyme replacement therapy in a follow-up manner. Methods: A case-control study was performed on 67 children (girls and boys) with GD who were recruited from the Children Welfare Hospital Consultation Clinic, the Gastroenterology and Hepatology Teaching Hospital, and the Central Child's Teaching Hospital. The levels of ALT, AST, total bilirubin (TB), and total protein (TP) were assessed in the samples of 67 Gaucher children, who were classified as recently diagnosed untreated patients (n=9), patients who received ERT for 3-6 months (n=18), 6-12 months (n=20), and patients who received ERT for more than one year (n=20), and compared to twenty newly comparable age-matched controls. The practical part of the study was conducted at research laboratories in the College of Pharmacy, Al-Maaql University and the Department of Pharmacy, Al-Turath University College during the period from December 2020 to March 2021. Results: The results showed that total protein levels in patients were significantly lower than in age-matched control group. The negative significant correlations between the levels of AST, ALT, and TB with the period of receiving treatment and the positive significant correlations between the levels of total protein and the period of receiving treatment indicated that the studied parameters were significantly associated with the period of receiving ERT. The effect of ERT was also indicated by the results of the ANOVA test, which revealed significant variations in the levels of ALT, AST, total bilirubin, and total protein across the patient subgroups. Conclusions: ALT, AST, total bilirubin, and total protein have been shown to have diagnostic significance in newly diagnosed untreated children with a wide range of treatment responses, limiting their utility in treatment monitoring.
Cite this article:
Haidar A. Abdulamir, Ameer A A Aldafaay, Ahmed Hamza Al-Shammari. The Role of Liver Function Tests in Monitoring the effect of Enzyme Replacement Therapy in Children with Gaucher Disease. Research Journal of Pharmacy and Technology. 2022; 15(8):3490-6. doi: 10.52711/0974-360X.2022.00585
Haidar A. Abdulamir, Ameer A A Aldafaay, Ahmed Hamza Al-Shammari. The Role of Liver Function Tests in Monitoring the effect of Enzyme Replacement Therapy in Children with Gaucher Disease. Research Journal of Pharmacy and Technology. 2022; 15(8):3490-6. doi: 10.52711/0974-360X.2022.00585 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-8-27
1. Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, Fahn S, Dorovski T, Chung WK, Pauciulo M, Nichols W, Rana HQ, Balwani M, Bier L, Elstein D, Zimran A. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol. 2014;71(6):752-7.
2. Kanneganti M, Kamba A, Mizoguchi E. Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol. 2012;5:1-9.
3. Chen Y, Sam R, Sharma P, Chen L, Do J, Sidransky E. Glucocerebrosidase as a therapeutic target for Parkinson's disease. Expert Opin Ther Targets. 2020;24(4):287-294.
4. Nagral A. Gaucher Disease. J Clin Exp Hepatol. 2014; 4(1): 37–50.
5. J. Krishnaveni, T. Ananthi. Hepatoprotective Effect of Moringa oleifera in Isoniazid Induced Rats. Research J. Pharm. and Tech. 4(12): Dec. 2011; Page 1901-1903.
6. Vrunda V. Shah, Vipul K. Shah, N. R. Sheth, M. M. Patel. Hepatoprotective and Anti-inflammatory activities of Hydroalcoholic extract of Bark of Erythrina indica. Res. J. Pharmacology and Pharmacodynamics. 2017; 9(4): 189-194. doi: 10.5958/2321-5836.2017.00033.7
7. Fadheelah S Azeez, Ali M Saadi. Evaluation of Liver Function in Type 2 Diabetic Patients during Clinical Trials in Kirkuk City. Research J. Pharm. and Tech. 2019; 12(4):1659-1663. doi: 10.5958/0974-360X.2019.00278.6
8. Amera Kamal Mohammed, Thanaa Abdulmahdi Mokif, Mahmoud Hussein Hadwan. The effect of Morbid Obesity on the Liver Function Enzymes. Research J. Pharm. and Tech. 2019; 12(5): 2241-2244. doi: 10.5958/0974-360X.2019.00373.1
9. Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab. 2015;12(2):157-64.
10. Peters H, Ellaway C, Nicholls K, Reardon K, Szer J. Treatable lysosomal storage diseases in the advent of disease-specific therapy. Intern Med J. 2020;50 Suppl 4:5-27.
11. Vaibhav Tripathi, Adeep Kujur, Manmeet Singh Saluja. Hepatoprotective Activity of Stem Bark of Nyctanthes arbor-tristis linn. Research Journal of Pharmacology and Pharmacodynamics. 2015; 7(3): 124-128. doi: 10.5958/2321-5836.2015.00023.3
12. Dr. P. Muthukumaran, Dr. V. Hazeena Begum. Effect of Poorna Chandrodayam Chendooram (PCM - Metallic Drug) on Lipid Profile, Liver Function and Kidney Function Parameters of Rats. Asian J. Pharm. Ana. 2020; 10(1):27-31. doi: 10.5958/2231-5675.2020.00006.X
13. Edokwe Chinelo, Obidoa Onyechi, Joshua Parker Elijah. Biochemical Effects of Persea americana (Avocado) and Dacryodes edulis (African Pear) Extracts on Liver Function Test of Albino Wistar Rats. Research J. Science and Tech. 2010; 2(2): 34-37 .
14. Limdi JK, Hyde GM. Evaluation of abnormal liver function tests. Postgrad Med J. 2003; 79(932):307-12.
15. B Suneetha, K V S R G Prasad, P. Deepthi Nishanthi, B R Soumya, B Sampath Kumar. Hepatoprotective and Antioxidant Activity of Methanolic Extract of Actinodaphne madraspatana against Carbon tetrachloride Induced Hepatotoxicity. Res. J. Pharmacognosy & Phytochem. 2014; 6(4): 176-180.
16. P Natarajan, A Thanga Thirupathi, T Raja Sekharan, AS William Arputha Sundar, R Arivukkarasu, M Ganesan. Hepatoprotective effect of Glinus oppositifolius Linn. Research J. Pharmacology and Pharmacodynamics. 2010; 2(4): 289-292.
17. Jinan Hussein Murtadha, Iman Hashim, Abdul Razzaq. Study of Liver Function and Lipid Profile Changes in Iraqi Cirrhotic patients. Research J. Pharm. and Tech. 2020; 13(4):1837-1840. doi: 10.5958/0974-360X.2020.00331.5
18. Shawky RM, Elsayed SM. Treatment options for patients with Gaucher Disease. The Egyptian Journal of Medical Human Genetics 2016;17: 281–285
19. Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016;11:28.
20. Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, Levade T, Astudillo L, Serratrice J, Brassier A, Rose C, Billette de Villemeur T, Berger MG. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. Int J Mol Sci. 2017;18(2). pii: E441.
21. Rizk TM, Ariganjoye RO, Alsaeed GI. Gaucher disease. Unusual presentation and mini-review. Neurosciences (Riyadh). 2015;20(3):271-6.
22. Hassan MH, Sayed AA, Ahmed AE, Saleem TH, Elsayh KI and Mohammed NBB. Effect of Enzyme Replacement Therapy on Disease Burden Biomarkers in Gaucher's Disease. International Journal of Biochemistry Research & Review 2016; 15(2): 1-6.